FIM
SRPT icon

Freedom Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Freedom Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,909
Closed -$304K – 897
2021
Q2 		$304K Sell
3,909
-235
-6% -$17.8K 0.02% 680
2021
Q1 		$309K Buy
+4,144
New +$382K 0.02% 665

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Freedom Investment Management's SRPT Position: Q3 2021 in Review

Freedom Investment Management sold out of Sarepta Therapeutics (SRPT) in Q3 2021, closing a stake of 3,909 shares — an estimated $304K sold.

Freedom Investment Management first reported a position in SRPT in Q1 2021 and held it in 2 quarters. The position peaked at $309K in Q1 2021. 306 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

  • Freedom Investment Management reported no remaining Sarepta Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Freedom Investment Management sold 3,909 Sarepta Therapeutics shares in Q3 2021, an estimated $304K.
  • Freedom Investment Management first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 2 quarters.
  • Freedom Investment Management's Sarepta Therapeutics position peaked at $309K in Q1 2021.
  • 306 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Freedom Investment Management's 13F filing for Q3 2021, filed 12 Nov 2021.